Rankings
▼
Calendar
ALKS Q4 2023 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena
ALKS
Alkermes plc
$5B
Q4 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$377M
+23.9% YoY
Gross Profit
$307M
81.4% margin
Operating Income
$179M
47.3% margin
Net Income
$113M
29.9% margin
EPS (Diluted)
$0.66
QoQ Revenue Growth
-0.9%
Cash Flow
Operating Cash Flow
$107M
Free Cash Flow
$90M
Stock-Based Comp.
$26M
Balance Sheet
Total Assets
$2.1B
Total Liabilities
$934M
Stockholders' Equity
$1.2B
Cash & Equivalents
$457M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$377M
$305M
+23.9%
Gross Profit
$307M
$251M
+22.6%
Operating Income
$179M
-$21M
+967.6%
Net Income
$113M
-$28M
+499.2%
Revenue Segments
Product
$705M
50%
Vivitrol
$304M
22%
Aristada And Aristada Initio
$248M
18%
L Y B A L V I
$154M
11%
← FY 2023
All Quarters
Q1 2024 →